Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Adris

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The Pharmacogenomics Journal|March 29, 2006
Hippocampal upregulation of the cyclooxygenase-2 gene following neonatal clomipramine treatment (a model of depression)P Cassano, A Hidalgo, V Burgos, et al.
The Journal of Investigative Dermatology|February 1, 1997
The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanomaF Ledda, A I Bravo, S Adris, et al.
Medicina|January 1, 1996
[The role of SPARC gene in tumorigenic capacity of human melanoma cells]M F Ledda, S Adris, L Bover, et al.
Gene Therapy|October 12, 1999
IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 responseS Adris, S Klein, M Jasnis, et al.
Cancer Gene Therapy|July 27, 1999
Different efficacy of in vivo herpes simplex virus thymidine kinase gene transduction and ganciclovir treatment on the inhibition of tumor growth of murine and human melanoma cells and rat glioblastoma cellsM Berenstein, S Adris, F Ledda, et al.
Nature Medicine|February 1, 1997
Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cellsM F Ledda, S Adris, A I Bravo, et al.
Cancer Research|December 16, 2000
Mice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cellsS Adris, E Chuluyan, A Bravo, et al.
Medicina|August 26, 1998
[Antitumor gene therapy using suicide genes]M Berenstein, S Adris, F Ledda, et al.
Cellular and Molecular Biology (Noisy-Le-Grand, France)|July 1, 1996
Tumor cells engineered to express interleukin-6 exhibit a reduced tumorigenicity depending on the tumor cell modelM F Ledda, S Adris, A I Bravo, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The Pharmacogenomics Journal|March 29, 2006
Hippocampal upregulation of the cyclooxygenase-2 gene following neonatal clomipramine treatment (a model of depression)P Cassano, A Hidalgo, V Burgos, et al.
The Journal of Investigative Dermatology|February 1, 1997
The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanomaF Ledda, A I Bravo, S Adris, et al.
Medicina|January 1, 1996
[The role of SPARC gene in tumorigenic capacity of human melanoma cells]M F Ledda, S Adris, L Bover, et al.
Gene Therapy|October 12, 1999
IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 responseS Adris, S Klein, M Jasnis, et al.
Cancer Gene Therapy|July 27, 1999
Different efficacy of in vivo herpes simplex virus thymidine kinase gene transduction and ganciclovir treatment on the inhibition of tumor growth of murine and human melanoma cells and rat glioblastoma cellsM Berenstein, S Adris, F Ledda, et al.
Nature Medicine|February 1, 1997
Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cellsM F Ledda, S Adris, A I Bravo, et al.
Cancer Research|December 16, 2000
Mice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cellsS Adris, E Chuluyan, A Bravo, et al.
Medicina|August 26, 1998
[Antitumor gene therapy using suicide genes]M Berenstein, S Adris, F Ledda, et al.
Cellular and Molecular Biology (Noisy-Le-Grand, France)|July 1, 1996
Tumor cells engineered to express interleukin-6 exhibit a reduced tumorigenicity depending on the tumor cell modelM F Ledda, S Adris, A I Bravo, et al.
Pageof 1